Skip to Content


Active Substance: eslicarbazepine acetate
Common Name: eslicarbazepine acetate
ATC Code: N03AF04
Marketing Authorisation Holder: BIAL - Portela & Ca, S.A.
Active Substance: eslicarbazepine acetate
Status: Withdrawn
Authorisation Date: 2009-04-21
Therapeutic Area: Epilepsy
Pharmacotherapeutic Group: Antiepileptics

Therapeutic Indication

Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.

The marketing authorisation for for Exalief has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.